Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease. Source
No articles found.
Windchime Health is here to help both patients and dentists. Their SaaS solution a...
Windchime Health is here to help both patients ...
Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing...
Axsome Therapeutics, Inc. is a clinical-stage b...
Smilelove offers clear aligner treatments direct-to-consumer: no expensive appoint...
Smilelove offers clear aligner treatments direc...
Sutro Biopharma, located in South San Francisco, is a clinical-stage drug discover...
Sutro Biopharma, located in South San Francisco...
Mereo BioPharma is a biopharmaceutical company focused on the development and comm...
Mereo BioPharma is a biopharmaceutical company ...
Intec Pharma is a clinical-stage biopharmaceutical company focused on developing d...
Intec Pharma is a clinical-stage biopharmaceuti...
Spring Bank is a clinical-stage biopharmaceutical company engaged in the discovery...
Spring Bank is a clinical-stage biopharmaceutic...
Join the National Investor Network and get the latest information with your interests in mind.